<DOC>
	<DOCNO>NCT00111579</DOCNO>
	<brief_summary>The purpose study describe level serum antibody confer CAIV-T TIV homotypic heterotypic influenza virus strain .</brief_summary>
	<brief_title>Study Evaluate Immune Responses Trivalent Cold-Adapted Influenza Vaccine ( CAIV-T ) Compared With ( TIV )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Male Female Ages 6 less 36 month ( reach 6th month yet reach 3rd birthday ) time randomization Written inform consent Health Insurance Portability Accountability Act ( HIPAA ) authorization ( applicable ) obtain participant 's parent/legal representative Ability parent/legal representative understand comply requirement study Parent/legal representative available telephone Ability complete followup period 180 day final study vaccination , require protocol History hypersensitivity component CAIVT TIV , include egg egg product , monosodium glutamate , porcine gelatin thimerosal History hypersensitivity gentamicin Any known immunosuppressive condition immune deficiency disease ( include HIV infection ) , ongoing receipt immunosuppressive therapy Household contact immunocompromised ( participant also avoid close contact immunocompromised individual least 21 day study vaccination ) History GuillainBarre syndrome Medically diagnose wheezing , bronchodilator use , steroid use ( systemic inhale ) , parent/legal representative report chart review , within 42 day prior randomization ( i.e. , child recent persistent asthma exclude ) ; history severe persistent asthma , accord criterion describe National Asthma Education Prevention Program ( NAEPP ) Expert Panel Report : Guidelines Diagnosis Management Asthma Update Selected Topics 2002 Acute febrile ( great 100.0 degree F oral equivalent ) and/or clinically significant respiratory illness ( e.g. , cough sore throat ) within 72 hour prior either study vaccination Use aspirin aspirincontaining product within 30 day prior randomization , expect use 180 day final study vaccination Receipt prior influenza vaccine Use antiinfluenza medication ( include amantadine , rimantadine , oseltamivir , zanamivir ) within 14 day prior randomization , expect use 180 day final study vaccination Administration live virus vaccine within 30 day prior randomization , expect receipt 30 day final study vaccination Administration inactivate ( i.e. , nonlive ) vaccine within 14 day prior randomization , expect receipt within 14 day , 14 day , either study vaccination Receipt investigational agent within 30 day prior randomization , expect receipt 180 day final study vaccination ( use license agent indication list package insert permit ) Receipt blood product within 90 day prior randomization , expect receipt 180 day final study vaccination Family member household contact employee research center otherwise involved conduct study Any condition , opinion investigator , would interfere evaluation vaccine interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>